IMMUTEP ADR WKN: A2H8YL ISIN: US45257L1089 Kürzel: IMMP Forum: Aktien Thema: Hauptdiskussion

Immutep Activities Report    January 29, 2020 08:00 ET | Source: Immutep Limited First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020 More mature data expected from TACTI-002 in February 2020 Sufficiently funded to deliver key upcoming catalysts http://www.globenewswire.com/news-release/2020/01/29/1976732/0/en/Immutep-Activities-Report.html

http://stocktwits.com/tripleface/message/191113215

Zu viert! 😉 Da ist ordentlich was in der Pipeline bei Immutep!

http://stocktwits.com/tripleface/message/190167735

Jupp q1 2020 ist interessant hier 😀

Oha jetzt sind wir schon zu dritt. :) es geht Berg auf

https://themarketherald.com.au/immutep-asximm-expands-part-c-of-tacti-002-study-due-to-positive-data-2020-01/

https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-limiteds-asximm-shift-from-loss-to-profit/

http://stocktwits.com/jeremy80/message/189609071

Near-Term Upside In LAG-3 Immunotherapy - Buy Immutep Summary LAG-3 - An emerging field in immunotherapy drug development. Immutep's 227 patient study in Metastatic Breast Cancer due to report in March 2020. Downside protection with Big Pharma relationships and multiple clinical trials currently underway. Undervalued stock with than US$100 million market capitalisation. Immutep (ASX:IMM, IMMP) is an Australian primarily listed biotechnology company working primarily in the field of cancer immunotherapy using the Lymphocyte Activation Gene 3 (LAG-3) immune control mechanism. Frederic Triebel, the Founder and Chief Scientist at Immutep, discovered in the late 1990s that a soluble protein called LAG-3 could activate dendritic cells in the vicinity of tumour https://seekingalpha.com/article/4313526?source=ansh $IMMP

Prof. Dr. Salah-Eddin Al-Batran, lead investigator of INSIGHT-004 commented: "We are really pleased that INSIGHT-004 recruitment is advancing and that we can start to enroll the second cohort of 6 patients. The treatment's safety profile is consistent with previous trials of efti which is encouraging and it's also good to see early activity signals with one patient reporting a partial response already."  INSIGHT-004 is the fourth arm of the INSIGHT trial which is being conducted by Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IKF). It is being conducted under Immutep's collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc and is evaluating the safety, tolerability and recommended Phase II dose of Immutep's lead immunotherapy product candidate efti when given in combination with avelumab in 12 patients with advanced solid malignancies. https://www.benzinga.com/pressreleases/19/12/g15016886/insight-004-clinical-trial-update

MARKET CAP 62,435,506 SHARES 34,117,763 AV. DAILY VOLUME 34,744 https://www.immutep.com/files/content/investor/investor-update/2017/2002185.pdf 112 gelistete Patente https://patentscope.wipo.int/search/en/result.jsf?_vid=P12-K52UDX-42431 9 klinische Studien https://clinicaltrials.gov/ct2/results?cond=&term=immutep&cntry=&state=&city=&dist=

Initial safety data from Phase I INSIGHT-004 Expected in Q4 CY2019 More mature data from TACTI-002 Expected in Q1 CY2020 First data from Phase IIb AIPAC Expected in Q1 CY2020 Final safety data from Phase I TACTI-mel Expected in H1 CY2020

WL Financing Update We were very pleased to have the ongoing support of our shareholders as we raised AU$4m in an equity placement and AU$6m from a fully underwritten Entitlement Offer in July 2019. Importantly, the funds raised are expected to extend the Company’s cash runway to the end of calendar year 2020, including a milestone payment of £4m (AU$7.4m) that we received from our partner GSK related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis. Partner milestone payments form an important source of non-dilutive funding for Immutep. The Company is eligible to receive up to £64m (~A$118.17m) in developmental milestone payments from GSK as well as single-digit tiered royalties, if GSK2831781 is commercialised. Overall the Company is in a solid financial position ahead of the coming milestones.

Oh ich besitze das Unternehmen alleine :)

Ist hier jemand?